XM does not provide services to residents of the United States of America.
E
E

Equifax

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Credit bureaus can’t bar NJ law requiring foreign language reports, US judge rules

UPDATE 1-Credit bureaus can’t bar NJ law requiring foreign language reports, US judge rules Adds comment from Consumer Data Industry Association in paragraph 8 By Mike Scarcella March 28 (Reuters) - New Jersey can require Equifax and other major credit bureaus to provide credit reports in non-English languages without violating the federal Fair Credit Reporting Act, a U.S.
E
E

Credit bureaus can’t bar NJ law requiring foreign language reports, US judge rules

Credit bureaus can’t bar NJ law requiring foreign language reports, US judge rules By Mike Scarcella March 28 (Reuters) - New Jersey can require Equifax and other major credit bureaus to provide credit reports in non-English languages without violating the federal Fair Credit Reporting Act, a U.S. judge has ruled. U.S. District Judge Georgette Castner in Trenton on Wednesday declined to strike down the state's multi-language requirement in a challenge brought by the Consumer Data Industry Asso
E
E

U.S. Agiliti, Domino's, Krystal Biotech

U.S. RESEARCH ROUNDUP-Agiliti, Domino's, Krystal Biotech Feb 27 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.listed companies including Agiliti, Domino's Pizza and Krystal Biotech on Tuesday. HIGHLIGHTS * Agiliti Inc AGTI.N : Jefferies cuts to hold from buy * Autodesk Inc ADSK.O : RBC raises target price to $290 from $280 * Domino's Pizza Inc DPZ.N : Jefferies raises target price to $455 from $400 * Itron Inc ITRI.O : Canaccord Genuity raises
A
B
S
W
F
F
W
D
E

Workday accused of facilitating widespread bias in novel AI lawsuit

Workday accused of facilitating widespread bias in novel AI lawsuit Screening software reflects existing bias, lawsuit claims Amended complaint follows judge's call for more specifics Explosion in employers' use of AI has led to few lawsuits By Daniel Wiessner Feb 21 (Reuters) - Workday is facing renewed claims that it uses artificial intelligence tools that discriminate against job applicants at many major companies it contracts with, in what could be one of the first cases to address the novel
E
E

U.S. An2 Therapeutics, Par Technology, Trimble

U.S. RESEARCH ROUNDUP-An2 Therapeutics, Par Technology, Trimble Feb 13 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including An2 Therapeutics, Par Technology and Trimble, on Tuesday. HIGHLIGHTS * An2 Therapeutics Inc ANTX.O : Leerink Partners cuts to market perform from outperform * Construction Partners Inc ROAD.O : Baird cuts to neutral rating * Cymabay Therapeutics Inc CBAY.O : B.
A
B
C
C
P
P
T
A
C
A
E
I

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.